Neoadjuvant Therapy in the Treatment of Breast Cancer

被引:116
作者
Teshome, Mediget [1 ]
Hunt, Kelly K. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
关键词
Breast cancer; Neoadjuvant chemotherapy; Preoperative chemotherapy; Pathologic complete response; PATHOLOGICAL COMPLETE RESPONSE; CHEMOTHERAPY PLUS TRASTUZUMAB; LOCAL-REGIONAL RECURRENCE; III RANDOMIZED GEPARTRIO; HORMONE-RECEPTOR STATUS; LYMPH-NODE SURGERY; PREOPERATIVE CHEMOTHERAPY; PHASE-II; PROGNOSTIC VALUE; PRIMARY TUMOR;
D O I
10.1016/j.soc.2014.03.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neoadjuvant systemic therapy in breast cancer treatment was initially utilized for inoperable disease. However, several randomized prospective studies have demonstrated comparable survival with adjuvant chemotherapy in early-stage, operable breast cancer while also decreasing tumor size facilitating breast conservation without significant increases in local recurrence. Response to therapy can predict outcome, with improved survival associated with pathologic complete response (pCR). Triple negative and HER2-positive subtypes show increased pCR rates. A multidisciplinary approach is necessary with neoadjuvant treatment. This can improve rates of breast conservation, provide insights into tumor biology and predict patient outcomes.
引用
收藏
页码:505 / +
页数:21
相关论文
共 65 条
[51]   Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: TBCRC 006 [J].
Rimawi, Mothaffar F. ;
Mayer, Ingrid A. ;
Forero, Andres ;
Nanda, Rita ;
Goetz, Matthew P. ;
Rodriguez, Angel A. ;
Pavlick, Anne C. ;
Wang, Tao ;
Hilsenbeck, Susan G. ;
Gutierrez, Carolina ;
Schiff, Rachel ;
Osborne, C. Kent ;
Chang, Jenny C. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (14) :1726-1731
[52]   Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) [J].
Schneeweiss, A. ;
Chia, S. ;
Hickish, T. ;
Harvey, V. ;
Eniu, A. ;
Hegg, R. ;
Tausch, C. ;
Seo, J. H. ;
Tsai, Y. -F. ;
Ratnayake, J. ;
McNally, V. ;
Ross, G. ;
Cortes, J. .
ANNALS OF ONCOLOGY, 2013, 24 (09) :2278-2284
[53]   Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study [J].
Semiglazov, V. ;
Eiermann, W. ;
Zambetti, M. ;
Manikhas, A. ;
Bozhok, A. ;
Lluch, A. ;
Tjulandin, S. ;
Sabadell, M. D. ;
Caballero, A. ;
Valagussa, P. ;
Baselga, J. ;
Gianni, L. .
EJSO, 2011, 37 (10) :856-863
[54]   Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer [J].
Semiglazov, Vladimir F. ;
Semiglazov, Vladislav V. ;
Dashyan, Garik A. ;
Ziltsova, Elena K. ;
Ivanov, Vadirn G. ;
Bozhok, Alla A. ;
Melnikova, Olga A. ;
Paltuev, Ruslan M. ;
Kletzel, Alexander ;
Berstein, Lev M. .
CANCER, 2007, 110 (02) :244-254
[55]   Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial [J].
Smith, IE ;
Dowsett, M ;
Ebbs, SR ;
Dixon, JM ;
Skene, A ;
Blohmer, JU ;
Ashley, SE ;
Francis, S ;
Boeddinghaus, I ;
Walsh, G .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5108-5116
[56]   Measurement of residual breast cancer burden to predict survival after Neoadjuvant chemotherapy [J].
Symmans, W. Fraser ;
Peintinger, Florentia ;
Hatzis, Christos ;
Rajan, Radhika ;
Kuerer, Henry ;
Valero, Vicente ;
Assad, Lina ;
Poniecka, Anna ;
Hennessy, Bryan ;
Green, Marjorie ;
Buzdar, Aman U. ;
Singletary, S. Eva ;
Hortobagyi, Gabriel N. ;
Pusztai, Lajos .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (28) :4414-4422
[57]   The Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Clinically Node-Negative Patients After Neoadjuvant Chemotherapy for Breast Cancer-A Systematic Review and Meta-Analysis [J].
Tan, Veronique K. M. ;
Goh, Brian K. P. ;
Fook-Chong, Stephanie ;
Khin, Lay-Wai ;
Wong, Wai-Keong ;
Yong, Wei-Sean .
JOURNAL OF SURGICAL ONCOLOGY, 2011, 104 (01) :97-103
[58]   Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial [J].
Untch, Michael ;
Loibl, Sibylle ;
Bischoff, Joachim ;
Eidtmann, Holger ;
Kaufmann, Manfred ;
Blohmer, Jens-Uwe ;
Hilfrich, Joern ;
Strumberg, Dirk ;
Fasching, Peter A. ;
Kreienberg, Rolf ;
Tesch, Hans ;
Hanusch, Claus ;
Gerber, Bernd ;
Rezai, Mahdi ;
Jackisch, Christian ;
Huober, Jens ;
Kuehn, Thorsten ;
Nekljudova, Valentina ;
von Minckwitz, Gunter .
LANCET ONCOLOGY, 2012, 13 (02) :135-144
[59]   Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups [J].
Untch, Michael ;
Fasching, Peter A. ;
Konecny, Gottfried E. ;
Hasmueller, Stephan ;
Lebeau, Annette ;
Kreienberg, Rolf ;
Camara, Oumar ;
Mueller, Volkmar ;
du Bois, Andreas ;
Kuehn, Thorsten ;
Stickeler, Elmar ;
Harbeck, Nadia ;
Hoess, Cornelia ;
Kahlert, Steffen ;
Beck, Thomas ;
Fett, Werner ;
Mehta, Keyur M. ;
von Minckwitz, Gunter ;
Loibl, Sibylle .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (25) :3351-3357
[60]   Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study [J].
Untch, Michael ;
Rezai, Mahdi ;
Loibl, Sibylle ;
Fasching, Peter A. ;
Huober, Jens ;
Tesch, Hans ;
Bauerfeind, Ingo ;
Hilfrich, Joern ;
Eidtmann, Holger ;
Gerber, Bernd ;
Hanusch, Claus ;
Kuehn, Thorsten ;
du Bois, Andreas ;
Blohmer, Jens-Uwe ;
Thomssen, Christoph ;
Costa, Serban Dan ;
Jackisch, Christian ;
Kaufmann, Manfred ;
Mehta, Keyur ;
von Minckwitz, Gunter .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) :2024-2031